NDA 221276 is the FDA application for HIBSAGO (bepirovirsen). The FDA's Orange Book lists the applicant of record as GLAXOSMITHKLINE LLC and the first approval on it as Oct 20, 2026. Code names used in development: GSK3228836, IONIS-HBVRx. Owner today: GSK plc (LSE/NYSE: GSK).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 221276 · Orange Book NDA 221276
| Brand name (FDA) | HIBSAGO Orange Book trade name: HIBSAGO |
|---|---|
| Active ingredient (FDA) | BEPIROVIRSEN SODIUM |
| Code name | GSK3228836 Source: Ionis Pharmaceuticals press release, Nov 8, 2022 “Bepirovirsen (formerly IONIS-HBVRx), also known as GSK3228836, was discovered, and jointly developed with GSK.” |
| Code name | IONIS-HBVRx Source: Ionis Pharmaceuticals press release, Nov 8, 2022 “Bepirovirsen (formerly IONIS-HBVRx), also known as GSK3228836, was discovered, and jointly developed with GSK.” |
| FDA applicant of record | GLAXOSMITHKLINE LLC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | GSK plc (GSK) Source: GSK press release, Oct 20, 2026 “GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved” |
| Earlier / partner | Ionis Pharmaceuticals (IONS): licensed the drug to the current owner Source: Ionis Pharmaceuticals press release, Nov 8, 2022 “GSK licensed bepirovirsen from Ionis in August 2019 under a collaborative development and licensing agreement.” … “Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | HIBSAGO | SOLUTION;SUBCUTANEOUS | EQ 150MG BASE/ML (EQ 150MG BASE/ML) | Oct 20, 2026 |
Drug page: /drug/bepirovirsen
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.